extract: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage

domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md

@@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
 
 The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
+
+CBO scored Medicare GLP-1 coverage at $35B additional spending over 2026-2034, while ASPE clinical economics analysis found net savings of $715M over 10 years from the same policy. The $35.7B divergence stems from CBO's conservative assumptions about uptake rates and limited counting of downstream savings (avoided hospitalizations, disease progression) within the 10-year budget window. ASPE's model includes 38,950 cardiovascular events avoided and 6,180 deaths avoided, which generate healthcare cost offsets that CBO methodology structurally undercounts.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16*
+
+ASPE's broad semaglutide access scenario projects 38,950 cardiovascular events avoided and 6,180 deaths avoided over 10 years among Medicare beneficiaries. The eligibility criteria require comorbidities (CVD history, heart failure, CKD, prediabetes) rather than BMI alone, targeting the population where multi-organ protection creates the highest clinical value. Approximately 10% of Medicare beneficiaries would be eligible under these criteria.
+
 ---
 
 Relevant Notes:

inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md

@@ -7,9 +7,13 @@ date: 2024-11-01
 domain: health
 secondary_domains: [internet-finance]
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,11 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
 EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
 
 flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
+
+
+## Key Facts
+- CBO estimates Medicare GLP-1 coverage would increase federal spending by $35 billion over 2026-2034
+- ASPE estimates net savings of $715 million over 10 years (range: $412M to $1.04B across scenarios)
+- Annual Part D cost increase projected at $3.1-6.1 billion
+- Approximately 10% of Medicare beneficiaries would be eligible under proposed comorbidity-based criteria
+- Broad semaglutide access projected to avoid 38,950 CV events and 6,180 deaths over 10 years